| Old Articles: <Older 1771-1780 Newer> |
|---|
 |
The Motley Fool
February 15, 2005
Carl Wherrett |
Nano Makes Another Delivery An Australian nanobio company might offer a nice return for early investors.   |
Bio-IT World
February 11, 2005
Kevin Davies |
The Galileo Code In searching 400 years of French-Canadian history for genetic clues to diseases among Quebec's founding population, Genizon BioSciences -- formerly Galileo Genomics -- is rapidly becoming the bio-IT company du jour. |
Bio-IT World
February 11, 2005
Malorye A. Branca |
Catching a Big Pharma Partner Deal flow: biotechs learn to squeeze value out of hot product deals when choosing a suitor. |
Bio-IT World
February 11, 2005
Robert M. Frederickson |
Genomics Drives New Crop of IVDs In vitro diagnostic microarrays are an important tool in oncology. The Affymetrix GeneChip System 3000Dx (GCS 3000Dx) was the first microarray instrument to be cleared by the FDA for IVD use. |
Bio-IT World
February 11, 2005
John Russell |
Frist's Fantastic Visions Realizing Senate majority leader Bill Frist's vision for the future of healthcare and the drug industry, laden with predictable "privatization" economic arguments and transforming technologies, will be quite a challenge. |
The Motley Fool
February 14, 2005
Rich Duprey |
Chiron Probe Goes Formal SEC upgrades investigation into vaccine manufacturer. Was Chiron was as surprised by the contamination debacle as investors and U.S. regulators were? |
The Motley Fool
February 14, 2005
Stephen D. Simpson |
Glaxo Stays Above the Fray The British drugmaker looks to regain momentum this year. Investors who are comfortable with the general industry risks and are looking for a relatively "clean" pharmaceutical company should do some research on Glaxo shares. |
The Motley Fool
February 14, 2005
Stephen D. Simpson |
Apria Needs a Breather Home care provider will feel the pinch from lower Medicare reimbursement. Valuation is not out of line, but that doesn't necessarily make these shares a bargain. |
The Motley Fool
February 11, 2005
Stephen D. Simpson |
For Alcon, the Eye Is the Prize Well-balanced growth continues to be the key to this ophthalmology giant. |
The Motley Fool
February 11, 2005
Stephen D. Simpson |
Cytyc Grows but Stays Focused Still concentrating on women's health, the company looks to move beyond its traditional diagnostics business. |
| <Older 1771-1780 Newer> Return to current articles. |
